Tirzepatide addresses multiple cardiovascular risk factors, including weight, insulin resistance, inflammation, and dyslipidemia, potentially providing a net cardiovascular benefit rather than introducing new risk
Zepbound was FDA-approved in 2023 for long-term weight management in adults with obesity (with a body mass index of 30 or higher) and overweight (with a body mass index of 27 or higher) with at least one weight-related condition, such as high blood pressure, type 2 diabetes, or high cholesterol
This was recently in the news
Trinity Family Medicine provides telehealth services to patients who are physically located in Texas* at the time of service.
This is because urinary glucose excretion by default falls or ceases when plasma glucose drops, but there can also be contributions through sympathetic nervous activation during hypoglycemia that reduces the glomerular filtration rate and hence glucosuria [67], as well as through increased hepatic gluconeogenesis [68]
M., Marcus, C., et al
